APGE AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
APGE Current Performance
2.65%
Apogee therapeutics inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to APGE
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
APM | Aptorum group ltd | 1 | 2 | 2 | 1 | 1 | |
LTRN | Lantern pharma inc | 2 | 2 | 3 | 1 | 1 | |
MNMD | Mind medicine (mindmed) inc | 1 | 4 | 2 | 3 | 1 | |
CRGX | Cargo therapeutics inc | - | 3 | 4 | 3 | 1 | |
KPTI | Karyopharm therapeutics inc | 3 | 3 | 4 | 3 | 1 |
- APM Aptorum group ltdValue 1Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
APGE Profile
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4R?. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.